CRISPR Therapeutics (CRSP) highlights strategic priorities and anticipated 2026 milestones; -Starting 2026 with a strong balance sheet with approximately USD 2bln in cash, cash equivalents, and marketable securities
CRISPR Therapeutics is positioning itself for a transformative 2026 with significant milestones and a robust balance sheet, suggesting strong operational health.
German Current Account (Nov) 15.1B vs. Exp. 15.1B (Prev. 14.8B )
Cuban President says there are no conversations with US Government, except for technical contacts in the migration field
CRISPR Therapeutics (CRSP) highlights strategic priorities and anticipated 2026 milestones; -Starting 2026 with a strong balance sheet with approximately USD 2bln in cash, cash equivalents, and marketable securities
German Finance Minister says price floors for rare earths is an option they will discuss at G7
German Finance Minister on Trump's Fed attack says central bank independence is a clear line for him as a finance minister
Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.
- Continued global commercialization and adoption of CASGEVY, with ongoing quarterly updates.
- Global regulatory submissions for CASGEVY in patients ages 5 – 11 are expected to be initiated by Vertex in the first half of 2026.
- Updates from CTX310® are expected in the second half of 2026.
- Updates from the Lp(a) program are expected in 2026.
- Top-line Phase 2 clinical data from CTX611 in patients undergoing total knee arthroplasty (TKA) are expected in the second half of 2026.
- Updates across autoimmune disease and immuno-oncology for zugocabtagene geleucel (zugo-cel; formerly CTX112™) are expected in the second half of 2026.
- The Company expects to initiate a clinical trial for CTX460 in alpha-1 antitrypsin deficiency (AATD) in mid-2026.
- The Company expects to initiate a clinical trial for CTX340 in refractory hypertension in the first half of 2026.
The planned updates and regulatory submissions reflect a focused push towards global commercialization of their therapies, which could significantly impact investor sentiment in both the biotech sector and broader markets. This proactive stance will likely be crucial in navigating the competitive landscape and could influence trading volumes and price movements ahead of key data releases.
Related headlines
- US EQUITY OPEN: US indices reverse initial CPI losses2 days ago
- Daily US Equity Opening News: ORCL gains on earnings and FY guidance beat; ADBE weighed by slight Q4 revenue miss; SMR downgraded2 days ago
- US FX WRAP: Dollar sees two-way action, but initially firms on hotter-than-expected core M/M print1 day ago
- Trump removes 50% tariff on bulk Canadian whisky and liquers, effective September 15th2 days ago
- Russian senior diplomat Ushakov says President Putin and Indian PM Modi discussed Ukraine during talks in New Delhi2 days ago
- Newsquawk European Market Wrap - 11th September 20262 days ago
- TREASURY WRAP: T-NOTE FUTURES (Z6) SETTLE 8 TICKS LOWER AT 106-03+1 day ago
- Newsquawk US Market Wrap: Markets chop, and yields flatten after hot core CPI boosts Fed rate hike bets1 day ago
- Saudi Arabia has signaled a potential willingness to launch a major unilateral military operation against the Houthis, though Riyadh has not yet reached a final decision, according to ABC1 day ago
- US President Trump reiterates USD 5k payment to all US adults will happen 1 day ago
- CRUDE WRAP: WTI (V6) SETTLES USD 2.43 LOWER AT 100.05/BBL; BRENT (X6) SETTLES USD 3.02 LOWER AT 104.61/BBL1 day ago
- A high-ranking Iranian security and political source told Al Mayadeen that contrary to claims and intimidation tactics, US President Trump is seeking to return to negotiations with Iran1 day ago
- Saudi Crown Prince MBS has personally urged President Trump to launch military strikes against Houthi forces in Yemen amid their rapid advance along the Red Sea coast, reports to CBS citing sources2 days ago
- Germany is developing a pharmaceutical pricing proposal for the Trump administration in an effort to avert potential US tariffs on German goods, reports Politico citing sources2 days ago
- Fed court reportedly blocks Trump order to keep Michigan coal plant open2 days ago
- US President Trump reiterates that Iran will never possess a nuclear weapon2 days ago
- Week in Focus 14-18th September 2026: Highlights include FOMC, BoJ, BoE, Inflation from UK, Canada and Japan1 day ago
- Week in Focus 14-18th September 2026: Highlights include FOMC, BoJ, BoE, Inflation from UK, Canada and Japan2 days ago
- JPMorgan revises Fed forecast and now sees hikes in September and December1 day ago
- Newsquawk Weekly Economic Calendar - 13th-18th September 20262 days ago
The whole workspace, free to try.
Try it free